EVLIN L. KINNEY, M.D.; JOANNE TRAUTMANN, Ph.D.; JAY ALEXANDER GOLD, J.D., M.P.H.; ELLIOT S. VESELL, M.D.; ROBERT ZELIS, M.D.
Young women serve less frequently than young men as subjects in premarketing clinical drug trials. Moral, legal, and medical implications of this underrepresentation of women are considered. Risks of medical harm to female patients can increase because medication is withheld. Also, risks of toxicity increase when women receive certain new drugs only in the postmarketing phase. Remedies to increase participation of young, nonpregnant women in clinical trials are discussed.
KINNEY EL, TRAUTMANN J, GOLD JA, VESELL ES, ZELIS R. Underrepresentation of Women in New Drug Trials: Ramifications and Remedies. Ann Intern Med. ;95:495–499. doi: 10.7326/0003-4819-95-4-495
Download citation file:
Published: Ann Intern Med. 1981;95(4):495-499.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use